Similar articles for PMID: 18405443

Year	Number of Results
1988	3
1992	1
1993	1
1994	1
1996	1
1997	1
1998	1
1999	3
2000	5
2001	7
2002	2
2003	6
2004	5
2005	9
2006	10
2007	19
2008	44
2009	24
2010	10
2011	2
2012	1
2013	1
2014	2
2021	1
2022	1
2024	0

1

The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.

Kehinde EO, Maghrebi MA, Anim JT. Kehinde EO, et al. Can J Urol. 2008 Apr;15(2):3967-74. Can J Urol. 2008. PMID: 18405443 Review.

2

The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.

Sinha AA, Quast BJ, Korkowski JC, Wilson MJ, Reddy PK, Ewing SL, Sloane BF, Gleason DF. Sinha AA, et al. Anticancer Res. 1999 Jul-Aug;19(4B):2821-9. Anticancer Res. 1999. PMID: 10652560

3

Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.

Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brünner N. Kos J, et al. Clin Cancer Res. 2000 Feb;6(2):505-11. Clin Cancer Res. 2000. PMID: 10690531

4

Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.

Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE. Hong SK, et al. Asian J Androl. 2008 Mar;10(2):207-13. doi: 10.1111/j.1745-7262.2008.00296.x. Epub 2007 Dec 20. Asian J Androl. 2008. PMID: 18097534 Free article.

5

Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.

Miyake H, Hara I, Eto H. Miyake H, et al. Anticancer Res. 2004 Jul-Aug;24(4):2573-7. Anticancer Res. 2004. PMID: 15330217 Free article.

6

New circulating biomarkers for prostate cancer.

Bensalah K, Lotan Y, Karam JA, Shariat SF. Bensalah K, et al. Prostate Cancer Prostatic Dis. 2008;11(2):112-20. doi: 10.1038/sj.pcan.4501026. Epub 2007 Nov 13. Prostate Cancer Prostatic Dis. 2008. PMID: 17998918 Review.

7

Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.

Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, Thiel RP, Taneja SS. Osman I, et al. J Urol. 2005 Dec;174(6):2174-7. doi: 10.1097/01.ju.0000181205.23233.65. J Urol. 2005. PMID: 16280758

8

Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

Tumminello FM, Flandina C, Crescimanno M, Leto G. Tumminello FM, et al. Biomed Pharmacother. 2008 Feb;62(2):130-5. doi: 10.1016/j.biopha.2007.07.001. Epub 2007 Jul 30. Biomed Pharmacother. 2008. PMID: 17728092

9

Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.

Milanese G, Dellabella M, Fazioli F, Pierpaoli E, Polito M, Siednius N, Montironi R, Blasi F, Muzzonigro G. Milanese G, et al. J Urol. 2009 Mar;181(3):1393-400. doi: 10.1016/j.juro.2008.10.147. Epub 2009 Jan 20. J Urol. 2009. PMID: 19157433

10

Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study.

Sinha AA, Morgan JL, Betre K, Wilson MJ, Le C, Marks LS. Sinha AA, et al. Anticancer Res. 2008 Jul-Aug;28(4B):2271-7. Anticancer Res. 2008. PMID: 18751406 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

147 results

Results by year